Laboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Wako, Saitama, Japan.
Neuroscience Research Laboratory, Institute of Mental Health and Neurosciences (IMHANS), Kozhikode, Kerala, India.
Mol Psychiatry. 2021 Dec;26(12):7550-7559. doi: 10.1038/s41380-021-01199-7. Epub 2021 Jul 15.
Recent evidence has documented the potential roles of histone-modifying enzymes in autism-spectrum disorder (ASD). Aberrant histone H3 lysine 9 (H3K9) dimethylation resulting from genetic variants in histone methyltransferases is known for neurodevelopmental and behavioral anomalies. However, a systematic examination of H3K9 methylation dynamics in ASD is lacking. Here we resequenced nine genes for histone methyltransferases and demethylases involved in H3K9 methylation in individuals with ASD and healthy controls using targeted next-generation sequencing. We identified a novel rare variant (A211S) in the SUV39H2, which was predicted to be deleterious. The variant showed strongly reduced histone methyltransferase activity in vitro. In silico analysis showed that the variant destabilizes the hydrophobic core and allosterically affects the enzyme activity. The Suv39h2-KO mice displayed hyperactivity and reduced behavioral flexibility in learning the tasks that required complex behavioral adaptation, which is relevant for ASD. The Suv39h2 deficit evoked an elevated expression of a subset of protocadherin β (Pcdhb) cluster genes in the embryonic brain, which is attributable to the loss of H3K9 trimethylation (me3) at the gene promoters. Reduced H3K9me3 persisted in the cerebellum of Suv39h2-deficient mice to an adult stage. Congruently, reduced expression of SUV39H1 and SUV39H2 in the postmortem brain samples of ASD individuals was observed, underscoring the role of H3K9me3 deficiency in ASD etiology. The present study provides direct evidence for the role of SUV39H2 in ASD and suggests a molecular cascade of SUV39H2 dysfunction leading to H3K9me3 deficiency followed by an untimely, elevated expression of Pcdhb cluster genes during early neurodevelopment.
最近的证据记录了组蛋白修饰酶在自闭症谱系障碍 (ASD) 中的潜在作用。已知组蛋白甲基转移酶中的遗传变异导致神经发育和行为异常的异常组蛋白 H3 赖氨酸 9 (H3K9) 二甲基化。然而,目前缺乏对 ASD 中 H3K9 甲基化动力学的系统研究。在这里,我们使用靶向下一代测序对 ASD 患者和健康对照者的 9 个参与 H3K9 甲基化的组蛋白甲基转移酶和去甲基酶基因进行了测序。我们在 SUV39H2 中发现了一个新的罕见变异(A211S),该变异被预测为有害。该变体在体外显示出强烈降低的组蛋白甲基转移酶活性。计算机分析表明,该变体使疏水性核心不稳定,并在变构上影响酶活性。Suv39h2-KO 小鼠在需要复杂行为适应的学习任务中表现出过度活跃和行为灵活性降低,这与 ASD 相关。Suv39h2 缺陷引起胚胎脑中一组原钙粘蛋白β (Pcdhb) 簇基因的表达升高,这归因于基因启动子处 H3K9 三甲基化 (me3) 的丧失。在 Suv39h2 缺陷型小鼠的小脑,H3K9me3 的减少持续到成年阶段。相应地,在 ASD 个体的死后大脑样本中观察到 SUV39H1 和 SUV39H2 的表达减少,这强调了 H3K9me3 缺乏在 ASD 病因学中的作用。本研究为 SUV39H2 在 ASD 中的作用提供了直接证据,并提出了 SUV39H2 功能障碍导致 H3K9me3 缺乏,随后在早期神经发育过程中 Pcdhb 簇基因表达过早升高的分子级联。